AZP-3404 is the first therapeutic peptide to leverage the biology of insulin-like growth factor binding protein 2 (IGFBP2), and to utilize multiple, well-established pathways to restore the body’s regulation of fat and glucose metabolism.
IGFBP2 is a protein that carries out the actions of leptin, a hormone that regulates fat and glucose metabolism. The ability of IGFBP2 to do this resides in a small peptide sequence within its structure. AZP-3404 is a stabilized peptide analog of this sequence and is the first drug candidate to reproduce and utilize the unique biology of IGFBP2.1,2,3
We are currently conducting pre-investigation new drug activities and exploring target indications for AZP-3404.
- Xi G, et al. “The Heparin-Binding Domains of IGFBP-2 Mediate Its Inhibitory Effect on Preadipocyte Differentiation and Fat Development in Male Mice.” Endocrinology. 2013 Nov; 154(11): 4146–4157.
- Xi G, et al. “A peptide containing the receptor binding site of insulin-like growth factor binding protein-2 enhances bone mass in ovariectomized rats.” Bone Res. 2018; 6, 23.
- Kawai M, et al. “The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton.” J Biol Chem. 2011 Apr 22;286(16):14670-80.